ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in St Louis, MO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near St Louis, MO, USA:

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

This study will look to establish the recommended biologic dose of AE37 in combination with pembrolizumab that will enhance the tumor-specif-...

Active, not recruiting
Triple-negative Breast Cancer
Biological: Pembrolizumab
Biological: AE37 Peptide vaccine

Phase 2

NuGenerex Immuno-Oncology

Swansea, Illinois, United States and 5 other locations

A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA)

of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Trastuzumab deruxtecan

Phase 1, Phase 2

AstraZeneca
AstraZeneca

St Louis, Missouri, United States and 31 other locations

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating lymph-...

Active, not recruiting
Triple Negative Breast Cancer
Procedure: Tumor biopsy
Biological: Cabiralizumab

Phase 1, Phase 2

The Washington University
The Washington University

Saint Louis, Missouri, United States

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

(SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC).The pri...

Enrolling
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy (SG)

Phase 1, Phase 2

Gilead Sciences
Gilead Sciences

St Louis, Missouri, United States and 14 other locations

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC). Usually, after neoadjuvant therapy and surgery for triple ne ...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Placebo

Phase 3

National Surgical Adjuvant Breast and Bowel Project Foundation (NSABP)

Swansea, Illinois, United States and 216 other locations

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen rec...

Enrolling
Breast Neoplasms
Drug: Paclitaxel
Drug: Iza-bren

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

O'Fallon, Illinois, United States and 259 other locations

Locations recently updated

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

St Louis, Missouri, United States and 276 other locations

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

(ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and ...

Active, not recruiting
Advanced Solid Tumors
Non-small-cell-lung-cancer (NSCLC)
Drug: ABBV-368
Drug: ABBV-927

Phase 1

AbbVie
AbbVie

Saint Louis, Missouri, United States and 26 other locations

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Active, not recruiting
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

St Louis, Missouri, United States and 275 other locations

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

(ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative...

Enrolling
Platinum Resistant High Grade Epithelial Ovarian Cancer
Triple Negative Breast Cancer
Drug: Itraconazole (ITZ)
Drug: ABBV-400

Phase 1

AbbVie
AbbVie

St Louis, Missouri, United States and 53 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems